+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are conducting a prospective online registry to explore the potential benefits and safety of external trigeminal nerve stimulation eTNS for treating migraines in pregnant women. The registry includes women with migraines or headaches who are pregnant, whether or not they use the eTNS device. The main goal is to determine if eTNS is a safe and effective option for migraine treatment during and after pregnancy. Participants are divided into two groups those who use the eTNS device during pregnancy and those who do not. Use of the device is not required to join the registry, and participants may start or stop using eTNS at any time without affecting their participation. The registry collects information entirely online through surveys completed at specific pregnancy and postpartum time points, including pre-pregnancy, each trimester, and early and late postpartum periods. Women enrolled will complete up to six surveys over about 12 months, covering health history, migraine symptoms, treatments, and mental health impacts. Participants using eTNS will answer additional questions about device use. Surveys are sent via email and text, with identity verification to protect data. The registry measures outcomes like the rate of miscarriage and postpartum bonding, with overall participation time estimated between 60 and 90 minutes.

Age: 18Years - 44YearsFEMALE
1 location
E

Actively Recruiting

Researchers are studying the use of a medical procedure involving the Bullfrog Micro-Infusion Device to deliver the anti-inflammatory drug dexamethasone sodium phosphate injection locally around deep veins after deep vein thrombosis DVT recanalization. This study focuses on patients who had DVT symptoms for up to 14 days before the recanalization. The goal is to evaluate whether this local anti-inflammatory treatment helps prevent re-thrombosis and improves symptoms for up to 24 months after the initial procedure. Participants are randomly assigned to receive either the perivascular dexamethasone treatment or a saline sham control delivered around the target vein segment using the catheter device. The study compares these two groups in a quadruple-masked design. Treatments are given following successful recanalization and removal of the acute thrombus from the femoropopliteal veins, which may extend into the iliac veins. During the study, participants will be monitored for the rate of vessel patency, progression to post-thrombotic syndrome, and major adverse events at specified time points up to 6 months and 30 days respectively. They will also follow prescribed anticoagulant and antiplatelet regimens post-procedure. Follow-up includes completion of questionnaires and study visits over up to 24 months to assess outcomes and safety under the lead sponsor Mercator MedSystems, Inc.

Age: 18Years - 89YearsAll GendersPhase 2
22 locations
M

Actively Recruiting

This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.

All AgesAll Genders
402 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the SELUTION SLR14 Drug Eluting Balloon DEB compared to plain uncoated balloon angioplasty in patients with peripheral arterial disease PAD affecting the below-the-knee BTK arteries, specifically in those with chronic limb-threatening ischemia CLTI. The study aims to show that the SELUTION SLR14 DEB has better efficacy and similar safety compared to the uncoated balloon treatment. Participants are adults aged 18 years or older with documented CLTI and significant narrowing in BTK arteries. The trial randomly assigns participants to one of two groups one receiving the SELUTION SLR14 DEB and the other receiving plain balloon angioplasty. Both are non-surgical procedures where a catheter inflates a balloon to open narrowed arteries below the knee. Treatments target specific lesions in BTK arteries and must meet detailed angiographic criteria. The study uses a single-blind design and includes follow-up assessments over several years. Participants will undergo evaluations at multiple time points including 30 days, 6 months, and up to 36 months after treatment. Assessments include clinical improvement, amputation rates, wound healing, imaging, and quality of life measures. Safety endpoints are monitored early, while efficacy outcomes are tracked long term. The study also evaluates device and procedural success immediately after treatment. Overall participation may last over three years to gather comprehensive safety and effectiveness data.

Age: 18Years +All GendersPhase Not Applicable
48 locations
E

Actively Recruiting

Researchers are evaluating the GORE4 VIABAHN4 FORTEGRA Venous Stent in a prospective, multicenter, single-arm post-market clinical study involving up to 35 sites in the U.S. The study focuses on patients with venous conditions needing treatment with this stent device. The purpose is to assess its use in real-world settings, monitoring safety and effectiveness in treating venous stenosis, occlusion, thromboses, and ulcers. Participants will receive the GORE4 VIABAHN4 FORTEGRA Venous Stent implanted at a clinical site. The procedure is guided by intraoperative imaging to ensure proper sizing and placement. After hospital discharge, participants return for follow-up visits at 1, 6, 12, 24, and 36 months to monitor the stents performance and any related health events. During the study, participants undergo evaluations including imaging to confirm stent patency and complications, and assessments of adverse events within 30 days and up to 36 months. The primary outcomes include safety events shortly after implantation and effectiveness at maintaining vessel openness after 12 months. Quality of life and technical success of the procedure are also measured. Participants are monitored for up to 3 years, with visits to assess their status and the devices function.

Age: 18Years +All GendersPhase Not Applicable
4 locations